Custom small-molecule oligonucleotide conjugation enables the attachment of ligands, vitamins, lipids, and affinity labels to siRNA, antisense oligonucleotides (ASO), and DNA/RNA probes. These conjugates improve cellular uptake, enable receptor-mediated targeting, and support detection or analytical workflows.
Small‑molecule oligonucleotide conjugates—often referred to as ligand‑conjugated oligonucleotides or oligonucleotide–ligand conjugates—are engineered constructs in which a defined non‑drug small molecule is covalently attached to an oligonucleotide such as siRNA, antisense oligonucleotides (ASO), DNA probes, or RNA strands. These ligands function as modular elements that enhance delivery, enable receptor‑mediated targeting, or introduce affinity labels used for detection, purification, and analytical workflows.
Depending on their functional role, small-molecule oligonucleotide conjugates are typically classified into three major categories: delivery modifiers, targeting ligands, and affinity labels. This modular design allows researchers to tune cellular uptake, biodistribution, receptor targeting, and assay performance without altering the oligonucleotide sequence.
Non-drug small molecules covalently attached to oligos to add delivery, targeting, or labeling function.
Tune uptake, biodistribution, receptor engagement, and assay performance without changing sequence.
Handle selection, linker/spacer design, conjugation, purification, and analytical confirmation.
siRNA, ASO, DNA, RNA, or probes. Scaffold chemistry influences tolerated attachment sites.
Controls sterics and solubility. PEG/alkyl spacers are commonly used to separate bulky ligands.
Defines the role: delivery modifier, targeting ligand, or affinity label (e.g., cholesterol, GalNAc, biotin).
Architecture of small-molecule oligonucleotide conjugates showing the oligonucleotide scaffold, linker/spacer, and functional small-molecule module.
Common applications include small‑molecule–siRNA conjugates, ligand‑conjugated ASOs, and biotin‑ and fluorophore‑labeled probes for analytical workflows.
Small-molecule oligonucleotide conjugates described on this page use non-drug small molecules that function as delivery modifiers, targeting ligands, or affinity labels. In contrast, oligonucleotide–drug conjugates (ODCs) carry a pharmacologically active payload (for example a cytotoxic agent or antibiotic), often paired with a cleavable linker to control release.
If your payload is an active drug, link visitors to your ODC pages: Oligonucleotide–drug conjugates →
Small molecules that influence uptake, biodistribution, membrane interaction, or intracellular trafficking.
Ligands that bind receptors or transporters to drive cell/tissue-selective uptake.
Tags that enable capture, imaging, or quantitation in research, QC, or diagnostic workflows.
Define oligo modality, attachment site, handle chemistry, spacer length, and ligand class (delivery/targeting/label).
Run chemistry optimized for selectivity and oligo integrity, with conversion tracking and cleanup.
Purify the conjugate and confirm identity/purity with orthogonal analytics suited to the ligand and oligo format.
Share modality (siRNA/ASO/DNA/RNA), intended function (delivery/targeting/label), preferred handle, and attachment site. We’ll recommend a spacer and chemistry path.
Delivery modifiers are small molecules installed to tune uptake and trafficking rather than to add drug activity. These conjugates can increase membrane interaction, alter clearance, or improve productive intracellular exposure—often through controlled changes in hydrophobicity and linker/spacer engineering.
Vitamin example: vitamin E derivatives (α-tocopherol) are commonly treated as delivery modifiers because they tune membrane interaction and hydrophobicity rather than act as a drug payload.
Explore more: siRNA conjugation → · ASO conjugation → · Oligonucleotide conjugation overview →
Targeting ligands drive selective uptake by binding receptors or transporters. This class includes clinically validated approaches (e.g., GalNAc) and widely used research ligands (e.g., folate). Ligand selection should align with your biology: receptor expression, internalization route, and intracellular delivery requirements.
Vitamin examples: folate (vitamin B9) and vitamin B12 (cobalamin) are often used as targeting ligands to engage receptor- or transporter-mediated uptake in selected models.
Affinity labels enable capture, imaging, or quantitative readouts. They are commonly used for probe development, pull-down assays, QC workflows, and diagnostic constructs.
High-affinity streptavidin capture for pull-downs, immobilization, and assay assembly.
Imaging and quantitation; choose dye to match readout and avoid quenching interactions.
Azide/alkyne/DBCO/tetrazine handles for post-synthesis labeling or modular assembly.
Explore more: Bioorthogonal oligonucleotide conjugation → · Oligonucleotide probe labeling → · Oligonucleotide conjugation overview →
Handle selection depends on payload functional groups, stability requirements, and whether you need orthogonal assembly.
For bioorthogonal-focused builds, link to your dedicated page: Bioorthogonal conjugation →
Choose 5′ vs 3′ vs internal sites based on mechanism and steric tolerance.
Spacer length can rescue solubility/purification when ligands are hydrophobic or bulky.
Hydrophobic ligands may require optimized purification conditions such as adjusted HPLC gradients or specialized stationary phases for clean separation.
Including specific molecule names helps visitors quickly map your goal to the right conjugate class (delivery modifier, targeting ligand, or affinity label).
Link these related platforms together to build a clear topical cluster for search engines and visitors.
Overview of attachment sites, handles, purification, and QC.
Duplex-specific placement strategy and ligand options.
Terminal vs internal placement and analytics for modified ASOs.
SPAAC (azide–DBCO) and tetrazine–TCO IEDDA for modular assembly.
ASGPR targeting for hepatocyte uptake and multivalency design.
Drug payload attachment, cleavable linkers, and controlled release.
Yes. Vitamin conjugates are small-molecule functional modules. Vitamin E is typically a delivery modifier, folate and vitamin B12 are usually targeting ligands, and biotin is most often an affinity label.
No. Here the small molecule is used for delivery/targeting/labeling. If the payload is pharmacologically active (e.g., cytotoxic, antibiotic), it should be described as an ODC and handled with controlled release/linker design considerations.
Start from payload functional groups and stability constraints. Common starting points include NH2 coupling and copper-free SPAAC (azide–DBCO). For staged/orthogonal builds, consider tetrazine–TCO IEDDA.
HPLC/UPLC confirms conversion and purity. LC-MS is used when compatible. Orthogonal confirmation (UV/Vis ratios, gel/CE) is selected based on construct and label.
For the fastest review, share: oligo modality/sequence (and strand info for siRNA), target application (delivery, targeting, or labeling), the small molecule (structure or catalog number), intended attachment site (5′/3′/internal), and preferred handle chemistry (NH2, SH, azide, DBCO, tetrazine/TCO).
If you’re not sure where a vitamin-based ligand or label fits, share your goal (delivery vs targeting vs labeling). We can recommend an attachment site, handle, and spacer strategy.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.